Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.

Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...

GSK is trying to bring its vaccine to market ahead of a rival jab from Pfizer, which is also anticipating regulatory approvals next year in both older adults and expectant mothers. Its vaccine is ...